Arch Biopartners Inc.
ACHFF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.96 | -0.93 | 1.17 | -0.83 |
| FCF Yield | 0.10% | -0.50% | -0.72% | -0.44% |
| EV / EBITDA | -649.51 | -2,333.07 | -1,391.32 | 0.00 |
| Quality | ||||
| ROIC | 22.58% | 42.43% | 24.91% | 72.77% |
| Gross Margin | 27.41% | 0.00% | 13.29% | 207.76% |
| Cash Conversion Ratio | -0.47 | 0.92 | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | 26.30% | 30.09% |
| Free Cash Flow Growth | 119.79% | 36.37% | -92.20% | 45.63% |
| Safety | ||||
| Net Debt / EBITDA | -12.38 | -46.82 | -29.93 | 0.00 |
| Interest Coverage | -4.68 | -8.80 | -5.09 | -9.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 32.58 | -1,007.72 | -937.01 | -767.69 |